From GlobeNewswire:

Amicus Therapeutics, a global biotechnology company, anticipates a 11-16% revenue growth in 2024 following a successful 2023. Total revenue for 2023 reached about $399.4 million, a 21% increase from the previous year, with approximately 2,400 people living with Fabry Disease using Galafold® as of 2023. The successful launch of Pombiliti + Opfolda is underway in the U.S., U.K., and Germany. Amicus intends to deliver double-digit Galafold revenue growth and advance ongoing studies to support medical and scientific leadership in Fabry and Pompe diseases in 2024 and expects to achieve full-year non-GAAP profitability. On a side note, the CEO Bradley Campbell will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 2:15 p.m. PT.



Read more: Amicus Therapeutics Reports Preliminary 2023 Revenue and